Ligand Pharmaceuticals LGND Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value?
- Ligand Pharmaceuticals (LGND) reported fair value measurement with unobservable inputs reconciliation recurring basis asset value of $5.21M in Q1 2026.
- How has Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value changed year-over-year?
- Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value decreased by 71.1% year-over-year, from $18.03M to $5.21M.
- What is the long-term trend for Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's fair value measurement with unobservable inputs reconciliation recurring basis asset value has grown at a 18.9% compound annual growth rate (CAGR), from $3.53M to $4.99M.